Lexicon Pharmaceuticals to Present New Clinical Data at 78th American Diabetes Association Scientific Sessions
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: GlobeNewswire
THE WOODLANDS, Texas, June 18, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), today announced that new clinical data for sotagliflozin will be presented at the upcoming 78th American Diabetes Association (ADA) Scientific Sessions in Orlando, FL, from June 22-26. The four accepted abstracts, including one oral presentation and two moderated poster discussions, reflect Lexicon and its collaborator, Sanofi’s efforts to address the unmet need for potential new options for the management of type 1 diabetes. Oral Presentation Sunday, June 24, 3:45pm, Oral Presentation Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1) (#212-OR) Moderated Poster Discussions Saturday, June 23, 12:30pm, Moderated Poster Discussion, “Clinical Outcomes with Oral Therapies” Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therap
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo [Yahoo! Finance]Yahoo! Finance
- Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & ExpoGlobeNewswire
- Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin [Yahoo! Finance]Yahoo! Finance
- New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease [Yahoo! Finance]Yahoo! Finance
- New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney DiseaseGlobeNewswire
LXRX
Earnings
- 3/11/24 - Beat
LXRX
Sec Filings
- 3/26/24 - Form ARS
- 3/26/24 - Form DEFA14A
- 3/26/24 - Form DEF
- LXRX's page on the SEC website